{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T01:15:36Z","timestamp":1784423736297,"version":"3.55.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Welcome Trust","doi-asserted-by":"crossref","award":["220211"],"award-info":[{"award-number":["220211"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-008203"],"award-info":[{"award-number":["INV-008203"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK Aid"},{"name":"M\u00e9decins sans Fronti\u00e8res (MSF) International"},{"DOI":"10.13039\/100009131","name":"Swiss Agency for Development and Cooperation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009131","id-type":"DOI","asserted-by":"crossref"}]},{"name":"German - Federal Ministry of Education and Research","award":["Kreditanstalt f\u00fcr Wiederaufbau"],"award-info":[{"award-number":["Kreditanstalt f\u00fcr Wiederaufbau"]}]},{"name":"United Kingdom \u2013 Department for International Development"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>To accelerate the progress towards onchocerciasis elimination, a macrofilaricidal drug that kills the adult parasite is urgently needed. Emodepside has shown macrofilaricidal activity against a variety of nematodes and is currently under clinical development for the treatment of onchocerciasis. The aims of this study were i) to characterize the population pharmacokinetic properties of emodepside, ii) to link its exposure to adverse events in healthy volunteers, and iii) to propose an optimized dosing regimen for a planned phase II study in onchocerciasis patients.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methodology \/ Principal findings<\/jats:title><jats:p>Plasma concentration-time profiles and adverse event data were obtained from 142 subjects enrolled in three phase I studies, including a single-dose, and a multiple-dose, dose-escalation study as well as a relative bioavailability study. Nonlinear mixed-effects modeling was used to evaluate the population pharmacokinetic properties of emodepside. Logistic regression modeling was used to link exposure to drug-related treatment-emergent adverse events (TEAEs). Emodepside pharmacokinetics were well described by a transit-absorption model, followed by a 3-compartment disposition model. Body weight was included as an allometric function and both food and formulation had a significant impact on absorption rate and relative bioavailability. All drug-related TEAEs were transient, and mild or moderate in severity. An increase in peak plasma concentration was associated with an increase in the odds of experiencing a drug-related TEAE of interest.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Conclusions\/Significance<\/jats:title><jats:p>Pharmacokinetic modeling and simulation was used to derive an optimized, body weight-based dosing regimen, which allows for achievement of extended emodepside exposures above target concentrations while maintaining acceptable tolerability margins.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pntd.0010219","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T18:56:37Z","timestamp":1646938597000},"page":"e0010219","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1146-3452","authenticated-orcid":true,"given":"Frauke","family":"Assmus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5322-912X","authenticated-orcid":true,"given":"Richard M.","family":"Hoglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Monnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Specht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-9289","authenticated-orcid":true,"given":"Ivan","family":"Scandale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4566-4030","authenticated-orcid":true,"given":"Joel","family":"Tarning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"pntd.0010219.ref001","unstructured":"World Health Organisation. Onchocerciasis, Key facts 2019, June 14 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/onchocerciasis."},{"issue":"47","key":"pntd.0010219.ref002","first-page":"633","article-title":"Progress report on the elimination of human onchocerciasis, 2017\u20132018.","volume":"93","year":"2018","journal-title":"Releve epidemiologique hebdomadaire."},{"issue":"4","key":"pntd.0010219.ref003","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0001-706X(91)90015-C","article-title":"The reproductive lifespan of Onchocerca volvulus in West African savanna","volume":"48","author":"AP Plaisier","year":"1991","journal-title":"Acta tropica"},{"issue":"1\u20132","key":"pntd.0010219.ref004","first-page":"27","article-title":"Observations on the reproductive biology of Onchocerca volvulus","volume":"59","author":"H. Schulz-Key","year":"1990","journal-title":"Acta Leidensia"},{"issue":"1","key":"pntd.0010219.ref005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1471-4922(01)02173-0","article-title":"Resistance and susceptibility in human onchocerciasis\u2014beyond Th1 vs. Th2","volume":"18","author":"A Hoerauf","year":"2002","journal-title":"Trends in parasitology"},{"issue":"Suppl 1","key":"pntd.0010219.ref006","doi-asserted-by":"crossref","first-page":"i28","DOI":"10.1093\/inthealth\/ihv077","article-title":"Neglected tropical diseases in Africa: a new paradigm.","volume":"8","author":"AD Hopkins","year":"2016","journal-title":"International health."},{"issue":"5","key":"pntd.0010219.ref007","doi-asserted-by":"crossref","first-page":"e0003507","DOI":"10.1371\/journal.pntd.0003507","article-title":"Growth, Challenges, and Solutions over 25 Years of Mectizan and the Impact on Onchocerciasis Control.","volume":"9","author":"J Lawrence","year":"2015","journal-title":"PLoS neglected tropical diseases."},{"key":"pntd.0010219.ref008","unstructured":"The Mectizan Donation Program. [Available from: https:\/\/mectizan.org\/.]"},{"issue":"Suppl 1","key":"pntd.0010219.ref009","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1475-2883-2-S1-S4","article-title":"Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon","volume":"2","author":"M Boussinesq","year":"2003","journal-title":"Filaria journal"},{"issue":"9070","key":"pntd.0010219.ref010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection","volume":"350","author":"J Gardon","year":"1997","journal-title":"Lancet (London, England)."},{"issue":"3","key":"pntd.0010219.ref011","doi-asserted-by":"crossref","first-page":"e998","DOI":"10.1371\/journal.pntd.0000998","article-title":"Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus.","volume":"5","author":"MY Osei-Atweneboana","year":"2011","journal-title":"PLoS neglected tropical diseases."},{"issue":"suppl_1","key":"pntd.0010219.ref012","doi-asserted-by":"crossref","first-page":"i40","DOI":"10.1093\/inthealth\/ihx054","article-title":"Alternative treatment strategies to accelerate the elimination of onchocerciasis.","volume":"10","author":"M Boussinesq","year":"2018","journal-title":"International health."},{"issue":"3","key":"pntd.0010219.ref013","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpddr.2016.04.002","article-title":"Research for new drugs for elimination of onchocerciasis in Africa","volume":"6","author":"AC Kuesel","year":"2016","journal-title":"International journal for parasitology Drugs and drug resistance"},{"issue":"1","key":"pntd.0010219.ref014","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40249-019-0567-z","article-title":"Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.","volume":"8","author":"G Gebrezgabiher","year":"2019","journal-title":"Infectious diseases of poverty."},{"key":"pntd.0010219.ref015","unstructured":"Wolrd Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases a roadmap for implementation. 2012."},{"issue":"1","key":"pntd.0010219.ref016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40249-018-0406-7","article-title":"From river blindness control to elimination: bridge over troubled water.","volume":"7","author":"R Colebunders","year":"2018","journal-title":"Infectious diseases of poverty."},{"key":"pntd.0010219.ref017","unstructured":"DNDi. Filaria: river blindness. accessed 3 March 2022 [Available from: https:\/\/dndi.org\/diseases\/filaria-river-blindness\/facts\/]"},{"issue":"3","key":"pntd.0010219.ref018","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0924-8579(03)00219-X","article-title":"Cyclooctadepsipeptides\u2014an anthelmintically active class of compounds exhibiting a novel mode of action","volume":"22","author":"A Harder","year":"2003","journal-title":"International journal of antimicrobial agents"},{"issue":"11","key":"pntd.0010219.ref019","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s004360100479","article-title":"Activity of the cyclic depsipeptide emodepside (BAY 44\u20134400) against larval and adult stages of nematodes in rodents and the influence on worm survival.","volume":"87","author":"A Harder","year":"2001","journal-title":"Parasitology research"},{"issue":"9","key":"pntd.0010219.ref020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.pt.2012.06.005","article-title":"Anthelmintic cyclcooctadepsipeptides: complex in structure and mode of action","volume":"28","author":"J Kr\u00fccken","year":"2012","journal-title":"Trends in parasitology"},{"key":"pntd.0010219.ref021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijpddr.2021.07.005","article-title":"Evaluation of the in vitro susceptibility of various filarial nematodes to emodepside","volume":"17","author":"MP H\u00fcbner","year":"2021","journal-title":"International journal for parasitology Drugs and drug resistance"},{"issue":"6","key":"pntd.0010219.ref022","doi-asserted-by":"crossref","first-page":"e1009601","DOI":"10.1371\/journal.ppat.1009601","article-title":"Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis.","volume":"17","author":"GS Bah","year":"2021","journal-title":"PLoS pathogens."},{"issue":"Pt 3","key":"pntd.0010219.ref023","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1017\/S0031182004006523","article-title":"Efficacy of two cyclooctadepsipeptides, PF1022A and emodepside, against anthelmintic-resistant nematodes in sheep and cattle","volume":"130","author":"G von Samson-Himmelstjerna","year":"2005","journal-title":"Parasitology"},{"issue":"10","key":"pntd.0010219.ref024","doi-asserted-by":"crossref","first-page":"e0004062","DOI":"10.1371\/journal.pntd.0004062","article-title":"The Cyclooctadepsipeptide Anthelmintic Emodepside Differentially Modulates Nematode, Insect and Human Calcium-Activated Potassium (SLO) Channel Alpha Subunits.","volume":"9","author":"A Crisford","year":"2015","journal-title":"PLoS neglected tropical diseases."},{"issue":"Suppl 1","key":"pntd.0010219.ref025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s00436-005-1438-z","article-title":"Mechanisms of action of emodepside","volume":"97","author":"A Harder","year":"2005","journal-title":"Parasitology research"},{"key":"pntd.0010219.ref026","unstructured":"DNDi. Emodepside accessed 2019, July 17 [Available from: http:\/\/www.dndi.org\/diseases-projects\/portfolio\/emodepside\/."},{"key":"pntd.0010219.ref027","article-title":"Safety, pharmacokinetics, relative bioavailability and dose linearity of four formulations of emodepside in healthy male subjects. accepted for publication","author":"J-Y Gillon","year":"2021","journal-title":"British J of Clin Pharm"},{"issue":"13","key":"pntd.0010219.ref028","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0020-7519(01)00263-6","article-title":"Filaricidal efficacy of anthelmintically active cyclodepsipeptides","volume":"31","author":"H Zahner","year":"2001","journal-title":"International journal for parasitology"},{"issue":"3","key":"pntd.0010219.ref029","doi-asserted-by":"crossref","DOI":"10.3390\/tropicalmed3030094","article-title":"Onchodermatitis: Where Are We Now?","volume":"3","author":"ME Murdoch","year":"2018","journal-title":"Tropical medicine and infectious disease"},{"key":"pntd.0010219.ref030","unstructured":"WHO World Health Organization. Onchocerciasis 14 June 2019 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/onchocerciasis."},{"key":"pntd.0010219.ref031"},{"issue":"5","key":"pntd.0010219.ref032","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"RM Savic","year":"2007","journal-title":"Journal of pharmacokinetics and pharmacodynamics"},{"issue":"6","key":"pntd.0010219.ref033","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0016-5085(84)80178-X","article-title":"The physiology and pathophysiology of gastric emptying in humans","volume":"86","author":"H Minami","year":"1984","journal-title":"Gastroenterology"},{"issue":"1","key":"pntd.0010219.ref034","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jvp.12149","article-title":"Brain penetration of emodepside is increased in P-glycoprotein-deficient mice and leads to neurotoxicosis","volume":"38","author":"S Elmshauser","year":"2015","journal-title":"Journal of veterinary pharmacology and therapeutics"},{"key":"pntd.0010219.ref035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"BJ Anderson","year":"2008","journal-title":"Annual review of pharmacology and toxicology"},{"key":"pntd.0010219.ref036","unstructured":"Elmsh\u00e4user, S., PhD thesis. (2015) Giessen : VVB Laufersweiler, Neurotoxizit\u00e4t von Emodepsid in Abh\u00e4ngigkeit der MDR1-Expression in der Blut-Hirn-Schranke"},{"issue":"4","key":"pntd.0010219.ref037","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1371\/journal.pntd.0000217","article-title":"Of mice, cattle, and humans: the immunology and treatment of river blindness","volume":"2","author":"JE Allen","year":"2008","journal-title":"PLoS neglected tropical diseases"},{"key":"pntd.0010219.ref038","unstructured":"DNDi. Clinical trial protocol. A Phase 1, Blinded, Randomized, Placebo-Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44\u20134400) After Oral Dosing in Healthy Male Subjects. 2017."}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T20:18:30Z","timestamp":1674937110000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010219"}},"subtitle":[],"editor":[{"given":"Gregory","family":"Deye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0010219","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]}}}